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Abstract Properdin stabilizes the alternative C3 convertase (C3bBb), whereas its role as pattern-
recognition molecule mediating complement activation is disputed for decades. Previously, we
have found that soluble collectin-12 (sCL-12) synergizes complement alternative pathway (AP)
activation. However, whether this observation is C3 dependent is unknown. By application of the
C3-inhibitor Cp40, we found that properdin in normal human serum bound to Aspergillus fumigatus
solely in a C3b-dependent manner. Cp40 also prevented properdin binding when properdin-
depleted serum reconstituted with purified properdin was applied, in analogy with the findings
achieved by C3-depleted serum. However, when opsonized with sCL-12, properdin bound in a C3-
independent manner exclusively via its tetrameric structure and directed in situ C3bBb assembly. In
conclusion, a prerequisite for properdin binding and in situ C3bBb assembly was the initial docking
of sCL-12. This implies a new important function of properdin in host defense bridging pattern
recognition and specific AP activation.
Introduction
Properdin was originally described in 1954 by Pillemer et al. as a serum component that promotes
complement activation in an antibody-independent manner (Pillemer et al., 1954). Since then, con-
troversies on how properdin facilitates complement activation have encircled. The first of the two
common conceptions are well accepted. Properdin binds to and stabilizes the alternative C3 conver-
tase C3bBb, thereby extending its half-life 5- to 10-fold and inhibit its degradation by factor I
(Fearon and Austen, 1975; Schreiber et al., 1975; Medicus et al., 1976). However, since chal-
lenged in 1958 by Nelson et al., who suggested that the binding of properdin requires the presence
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of activator-bound C3b, the second conception on the role of properdin as a pattern-recognition
molecule (PRM) leading to the alternative pathway (AP) activation has been a matter of dispute (Nel-
son, 1958; Kemper et al., 2010).
Recently, the concept of properdin as a PRM emerged from a series of studies designed to
understand whether properdin could initiate and direct in situ C3 convertase assembly. Interest in
this concept was renewed when recombinant transmembrane properdin in HEK-293 cells was shown
to initiate AP activation (Vuagnat et al., 2000) and surface plasmon resonance methodology con-
firmed that biosensor chip bound properdin can provide a platform to initiate C3bBbP assembly
from purified C3b, factor B and factor D (Hourcade, 2006). In line with those findings, several recent
observations have also supported the recognition role of properdin in several models of molecular
patterns including pathogens, endogenous cells and various biological substrates (Cortes et al.,
2011; Kemper et al., 2008; Xu et al., 2008; Saggu et al., 2013; O’Flynn et al., 2014; Wang et al.,
2015). However, Harboe et al. recently challenged the concept of properdin as a PRM and argued
that properdin binding to complement activating surfaces expressing pathogen- and damage-associ-
ated molecular patterns, including zymozan, Escherichia coli, Neisseria meningitidis, myeloperoxi-
dase and umbilical vein cells, is strictly dependent on initial C3 activation with subsequent binding of
properdin to stabilize C3bBb (Harboe et al., 2012; Harboe et al., 2017).
Collectin-12 (CL-12; also known as collectin placenta one or CL-P1) is a newly identified collagen-
like molecule with multimeric structure assembled by ~140 kDa subunits and mainly present as a
monomer, dimer or trimer (Nakamura et al., 2001; Ohtani et al., 2001; Ma et al., 2015). CL-12 is
characterized by an intracytoplasmic domain, a transmembrane domain and an ectodomain subdi-
vided into a coiled-coil domain, a collagen-like domain and a carbohydrate-recognition domain. The
ectodomain is crucial for oligomeric assembly and recognition of various pathogenic or endogenous
molecular patterns (Nakamura et al., 2001; Ohtani et al., 2001; Mori et al., 2014). CL-12 was origi-
nally defined as scavenger receptor C-type lectin because it shares structural and functional similari-
ties with type A scavenger receptor (Nakamura et al., 2001; Ohtani et al., 2001). CL-12 is mainly
expressed as transmembrane molecules on cells originating from the endothelium and placenta but
is also found on gastric stromal cells and phagocytes such as alveolar macrophages, central nervous
system resident macrophages and microglia cells. CL-12 has been shown to mediate scavenging
properties in sequestration of damage-associated molecular patterns such as oxidized low-density
lipoprotein (Nakamura et al., 2001; Ohtani et al., 2001; Selman et al., 2008). Furthermore, CL-12
binds glycans bearing both terminal galactose and fucose moieties and presents a striking high affin-
ity for LewisX trisaccharides (Coombs et al., 2005).
LewisX trisaccharides are commonly displayed on adhesion molecules of various leukocytes, sug-
gesting that CL-12 could modulate leukocyte recruitment (Coombs et al., 2005; Elola et al., 2007).
CL-12 has also been shown to bind fibrillar b-amyloid protein, thus indicating a potential role in scav-
enging of amyloid (Nakamura et al., 2006). More recent data show that CL-12 is involved in myelin
internalization by central nervous system resident phagocytes (Bogie et al., 2017). Moreover, CL-12
as a C-type lectin exhibits innate immune defense characteristics mediating phagocytosis of certain
bacteria and fungi (Ohtani et al., 2001; Jang et al., 2009; Zhang et al., 2019). Further, in a recent
study Chang et al. suggested the importance of CL-12 as a C-type lectin receptor involved in H.
pylori-gastric stromal cells interaction and mediating crosstalk between these cells and dendritic cells
(Chang et al., 2018). Finally, and particularly important for the background of this study, surface-
bound CL-12 has been suggested to play a role in complement activation through the classical path-
way via its association with C-reactive protein and C1q (Roy et al., 2017).
In previous work, we showed the existence of a soluble form of CL-12 in addition to the trans-
membrane form and revealed its specific opsonic properties towards clinically important fungal
pathogens (Ma et al., 2015; Zhang et al., 2019). Interestingly, we found that soluble CL-12 could
synergize AP activation upon opsonization of A. fumigatus leading to activation of C3 and the termi-
nal membrane attack complex formation (Ma et al., 2015). Thus, the present study aimed to investi-
gate whether and how soluble CL-12 opsonizing A. fumigatus interacts with properdin in a C3-
independent manner and leads to specific AP activation.
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Results
C3b and properdin deposition on A. fumigatus incubated in normal
human serum was C3-dependent
Compstatin is a potent peptide inhibitor of C3 activation, which has been further modulated to a
more potent analog named Cp40 (Risitano et al., 2014). In order to study our hypothesis, Aspergil-
lus fumigatus (A. fumigatus) was used as a model of infection. Normal human serum (NHS) was used
as a complement source and C3b deposition and properdin binding were determined on A. fumiga-
tus with or without the addition of Cp40. Cp40 completely inhibited C3b deposition at 1.5 mM final
concentration (Figure 1A). Concomitant with this observation, properdin binding was completely
abolished in the presence of the Cp40 (6 mM) (Figure 1B). A control peptide had no effects on C3b
or properdin binding (Figure 1A–B).
Soluble CL-12-induced properdin binding was not dependent on initial
C3b deposition
First, A. fumigatus was incubated with purified CL-12, and binding of CL-12 was measured by flow
cytometry (Figure 2A). Second, A. fumigatus was incubated with NHS, and the deposition of proper-
din was found to be markedly increased on the fungi opsonized with CL-12 than the non-opsonized
fungi (Figure 2B). Third, to further validate our previous findings that soluble CL-12 triggers AP
Figure 1. Inhibition of complement activation by compstatin analog Cp40. NHS (20%) was preincubated with compstatin analog Cp40 or its control
peptide (A: 0 ~ 6 mM; B: 6 mM) prior to inducing complement activation on A. fumigatus through incubation in the presence of Ca2+. C3b deposition (A)
or properdin binding (B) was analyzed and expressed as the geometric mean fluorescence intensity (GMFI) by flow cytometry. Data are expressed as
mean ± S.E.M from three independent experiments. Results are representative of at least six independent experiments. *p<0.01.
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Figure 2. Binding of properdin to A.fumigatus in the presence of soluble CL-12 and compstatin analog Cp40. A. fumigatus were incubated with or
without soluble CL-12 (sCL-12) (5 mg/ml) prior to addition of NHS (20%) under EGTA-Mg2+ buffer. In some experiments, NHS (20%) was preincubated
with compstatin analog Cp40 (6 mM) prior to induce complement activation. CL-12 (A) or properdin (B, C) binding was analyzed by flow cytometry.
Results are representative of at least six independent experiments.
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complement activation via properdin, C3 activation was inhibited by Cp40 and the effect of soluble
CL-12 on properdin recruitment was evaluated. In the presence of Cp40, properdin binding from
NHS alone was completely abolished, whereas properdin from NHS was still able to bind CL-12-pre-
opsonized fungi, although to a lesser extent than without Cp40. (Figure 2C).
Soluble CL-12 mediated C3b-independent binding of properdin
To further investigate the CL-12-dependent properdin binding, properdin-depleted serum (fP-Dpl)
was reconstituted with serum properdin in the absence and presence of Cp40. In the absence of
Cp40, no binding of properdin was observed in fP-Dpl, whereas after reconstitution the binding of
properdin was comparable to NHS as described above (Figure 3A). Pre-opsonization with CL-12
markedly enhanced the properdin binding in reconstituted serum (Figure 3A). C3 inhibition by Cp40
again virtually abolished the properdin binding to the fungi in the absence of CL-12, whereas it was
restored solely upon pre-opsonization with soluble CL-12 (Figure 3B).
The binding of properdin to CL-12-opsonized fungi was specifically C3-
independent
To further substantiate the exclusive effect of soluble CL-12 on C3b-independent binding of proper-
din, C3- depleted serum (C3-Dpl) was used as complement source to exclude the influence of C3b
deposition and properdin binding was determined with a series of serial dilution of the serum (~10–
100%). Reconstitution with exogenous C3 under physiological concentration was able to restore AP
activation as validated by determination of C3b deposition using the EGTA-Mg2+ containing buffer
(Figure 4A). Again, when A. fumigatus was opsonized with soluble CL-12, properdin binding was
markedly increased in a serum concentration-dependent manner, (Figure 4B), thus reflecting the
increase in properdin concentration with constant depleted C3. This was also confirmed through
application of 100% NHS (Figure 4C–E), where C3 activation (Figure 4C) and properdin binding
(Figure 4E) were completely removed by addition of the Cp40.
To further confirm the prerequisite of soluble CL-12 for the C3b-independent binding of proper-
din leading to complement activation observed with A. fumigatus, we turned to Aspergillus niger (A.
niger) as an another model of infection based on our recent findings (Zhang et al., 2019). In agree-
ment with the results for A. fumigatus, soluble CL-12-mediated properdin binding was detected in
NHS in the presence of Cp40 (Figure 4—figure supplement 1) or fP-Dpl plus exogeneous proper-
din (Figure 4—figure supplement 2) and was repeated with the use of C3-Dpl serum (Figure 4—
figure supplement 3). By contrast, when Candida albicans (C. albicans) was applied, no apparent
binding of soluble CL-12 was noted (Zhang et al., 2019) and complement was only activated in
mannose-binding lectin (MBL) (or collectin-11)-dependent manner (Ma et al., 2013a).
Soluble CL-12 solely recruits properdin with high oligomeric structure
To identify which structural organization is required for the interaction of soluble CL-12 with the olig-
omeric forms of properdin, recombinant wild type properdin was produced in HEK293F cells and
separated by size-exclusion chromatography (SEC) in two fractions: (i) containing dimers and trimers
(fP DT) and (ii) containing tetramers (fP T) (Pedersen et al., 2017). Furthermore, a monomer-like pro-
perdin (fP M) was manipulated and obtained through co-expression of separate N-terminal (TB-
TSR3) and C-terminal (TSR4-TSR6) constructs (Figure 5A; Pedersen et al., 2019a). The purity and
oligomerization status of these properdin preparations were confirmed by SDS-PAGE (Figure 5B,
inset) and by SEC analysis (Figure 5B). In the SDS-PAGE analysis, both fP T and fP DT migrated with
gel mobility corresponding to ~53 kDa in parallel with purified serum properdin, whereas the mono-
mer-like properdin comprising the two fragments TB-TSR3 and TSR4-TSR6 appeared as two bands
corresponding to ~33 kDa and ~31 kDa, respectively (Figure 5B, inset). Compared with purified
serum properdin organized mainly as dimer, trimer and tetramer, SEC analysis revealed that the
used fP DT contained approx. 50% dimers and 50% trimers eluting in two separate peaks, the fP T
was primarily tetrameric with a low content of trimer, while the fP M eluted in a single peak in line
with our previous observations (Figure 5B; Pedersen et al., 2017; Pedersen et al., 2019a). All three
properdin variants recognized C3b deposited on the fungus and induced C3 amplification via stabili-
zation of the C3 convertase (Figure 5C), consistent with our previous findings (Pedersen et al.,
2017; Pedersen et al., 2019a). Consistently, pre-opsonization with CL-12 enhanced the binding of
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Figure 3. Soluble CL-12-dependent properdin binding on A.fumigatus. A. fumigatus were incubated with or without sCL-12 (5 mg/ml) prior to addition
of properdin-depleted serum (fP-Dpl) (10%) reconstituted with serum properdin (10 mg/ml) (A). In some experiments, the serum was preincubated with
or without compstatin analog Cp40 (6 mM) under EGTA-Mg2+ buffer (B). Properdin binding was analyzed by flow cytometry. The GMFI was used to
Figure 3 continued on next page
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fP T dose-dependently in the presence of Cp40 (Figure 5D). In contrast, no clear binding was
detected when adding the fP DT or the fP M instead (Figure 5D). These results obtained with A.
fumigatus were confirmed by parallel experiments with A. niger (Figure 5E and Figure 5—figure
supplement 1).
Soluble CL-12-induced properdin binding directs in situ assembly of the
AP C3 convertase
To further validate whether surface-bound properdin directs C3bBb assembly and whether prior
opsonization of CL-12 indeed amplifies in situ assembly of C3bBb via properdin recruitment, Bb
deposition was assessed on A. fumigatus. In contrast to properdin-deficient serum, reconstitution of
exogeneous properdin sustained C3b-dependent Bb association, since no Bb deposition was
observed when Cp40 was present (Figure 6). In accordance with the previous properdin binding
data, pre-opsonization with CL-12 dramatically increased the Bb deposition in the reconstituted
serum, while C3 inhibition by Cp40 again abolished the Bb deposition (Figure 6). Consistent results
were also obtained on A. niger (Figure 6—figure supplement 1).
Discussion
Properdin is well established as a stabilizer of the AP convertase (Fearon and Austen, 1975;
Schreiber et al., 1975; Medicus et al., 1976). We have previously shown that properdin does not
recognize pathogenic or endogenous molecular patterns unless C3 is activated (Harboe et al.,
2012; Harboe et al., 2017). Here we, to the best of our knowledge, for the first time show that pro-
perdin might bind secondarily to a PRM, CL-12, opsonized on A. fumigatus, in a C3-independent
manner as illustrated in Figure 7.
CL-12 is a newly identified scavenger receptor C-type lectin and mainly expressed not only on
endothelial and placental cells, but also on gastric stromal cells and some phagocytes
(Nakamura et al., 2001; Ohtani et al., 2001; Selman et al., 2008; Chang et al., 2018). Recent data
have shown that some of the macrophage-specific scavenger receptors, for instance, scavenger
receptor/collagen-like domain 163 (CD163) and endocytic mannose receptor (MR, CD206), can be
found as soluble proteins produced by proteolytic cleavage of the receptors from the cell membrane
during inflammation and by macrophage activation (Etzerodt and Moestrup, 2013; Møller, 2012).
Both CD163 and CD206 have recently been detected in blood samples, and the levels have been
found to be closely associated with several disease states including infections and some liver dis-
eases (Møller, 2012; Rødgaard-Hansen et al., 2014; Andersen et al., 2018; Loonen et al., 2019;
Rødgaard-Hansen et al., 2015). It has been shown that soluble forms of CD163 and CD206 can be
shed from macrophages in contact with bacteria and fungi and promote opsonophagocytosis of S.
aureus (Kneidl et al., 2012), C. albicans and A. fumigatus (Gazi et al., 2011). These observations
imply that soluble forms of scavenger receptors may be generated under certain pathophysiological
conditions. In agreement with this, we have previously demonstrated generation of soluble CL-12
from the cell-bound form Ma et al., 2015. The soluble CL-12 was found to retain the capability to
recognize certain fungal pathogens such as A. fumigatus, Lichtheimia corymbifera, Mucor circinel-
loides etc (Zhang et al., 2019). Moreover, soluble CL-12 stimulated AP complement activation,
most likely via properdin, but the mechanism of this observation was not investigated further.
Whether properdin can function as a PRM and initiate in situ assembly of C3bBb amplifying com-
plement activation is controversial (Harboe et al., 2017). The function of properdin as a PRM has
been mostly investigated either under the presence of possible contribution from serum-generated
C3 activation or under conditions where non-physiological forms of properdin appears to initiate AP
activation, Thus, it is still controversial to define properdin as a complement initiating molecule in
addition to its C3bBb stabilizing function (Cortes et al., 2011; Kemper et al., 2008; Xu et al.,
2008; Saggu et al., 2013; O’Flynn et al., 2014; Wang et al., 2015). Despite this contention, surface
plasmon resonance analysis has clearly shown that properdin-immobilized biosensor chips can
Figure 3 continued
assess protein binding. B is expressed as mean ± S.E.M from three independent experiments. Results are representative of at least six independent
experiments. *p<0.01.
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Figure 4. Effect of soluble CL-12 on properdin binding in C3-absent serum. A. fumigatus was incubated with C3-depleted serum (C3-Dpl) (10%)
reconstituted with exogeneous C3 (130 mg/ml) (A). In some experiments, A. fumigatus was incubated with or without sCL-12 (5 mg/ml) prior to addition
of C3-Dpl (11.1 ~ 100%) (B). Inhibitory effect of compstatin analog Cp40 (20 mM) was determined on NHS (100%)-induced complement activation as
Figure 4 continued on next page
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initiate C3bBb assembly upon addition of purified C3b, factor B and factor D (Hourcade, 2006).
However, extrapolating this finding to a biologically relevant condition has been disputed since pro-
perdin covalently linked to biosensor chip might be in a non-physiological aggregated form. Never-
theless, this finding might imply that given a proper ‘sensory’ input it seems plausible that properdin
mediates de novo assembly of C3bBb. However, recent studies challenged and revised the view of
properdin as a PRM, suggesting that properdin binding to the AP activator surfaces happens solely
in a C3-dependent manner (Harboe et al., 2012; Harboe et al., 2017; Agarwal et al., 2010). In
agreement with these observations, our data consistently show that properdin does not bind directly
to Aspergillus strains, suggesting that properdin itself does not have potential to act as the AP initi-
ating molecule on this AP activator matrix. However, our previous findings show that properdin can
synergize the AP activation, C3 deposition and formation of terminal membrane attack complex on
A. fumigatus in the presence of soluble CL-12 whereas no clear effect of CL-12 was found on C4 acti-
vation (Ma et al., 2015). By contrast, CL-12 could not recognize another opportunistic fungal patho-
gen C. albicans. Without CL-12 opsonization, complement activation is dependent on the lectin
pathway via MBL and collectin-11 on C. albicans (Ma et al., 2013a). These findings imply the specific
binding and exclusive effector mechanism of CL-12 against certain pathogens.
In the present study, we asked the question of whether properdin might promote AP activation
specifically in a soluble CL-12-dependent manner independent of prior C3 deposition. Through con-
trol of initial C3 activation by the C3 blocker compstatin analog Cp40 and application of Aspergillus
stains as a model of infection, we provide evidence that properdin binds to the fungal pathogens
just after initial opsonization by soluble CL-12, but independent of C3, thus directing in situ assembly
of C3bBb. Therefore, the evidence herein supports the conception that properdin itself may spark
AP activation as a member of a hetero-PRMs complex comprising CL-12 as the PRM molecule bind-
ing in a C3-independent manner. In addition to complement amplification, the potential physiologi-
cal consequences of the soluble CL-12:properdin crosstalk in host defense against infections of
Aspergillus strains are intriguing and remain question. Previously, properdin binding to endothelial
cells has been suggested, largely based on surface expression of heparin sulfate proteoglycans to
attract properdin on vascular endothelial cells and renal tubular epithelial cells (Zaferani et al.,
2011; Mertens et al., 1992). However, even though endothelial cells contribute as source of serum
properdin and express heparin sulfate proteoglycans, no data exist to support direct binding of pro-
perdin to endothelial cells. Furthermore, a recent report has shown that the presence of the Cp40
can completely abolish properdin binding on human umbilical vein endothelial cells (HUVECs), sug-
gesting that properdin binding is secondary to initial C3b deposition (Harboe et al., 2017). In this
case, it is noteworthy that as a significant source of transmembrane scavenger receptor CL-12, vas-
cular endothelial cells, for instance, HUVECs, are likely to express a considerable level of CL-12. In
analogy with this finding, we did not observe any apparent binding of properdin to either CHO/CL-
12FL, HUVECs or HUAECs, even though these cells were determined to express transmembrane CL-
12 (Ma et al., 2015). However, our previous data clearly show that properdin could directly interact
with soluble form of CL-12 in a microtiter plate and cell-based setup as well (Ma et al., 2015). Com-
bining these data, it implies that CL-12 in its soluble form, when bound to a ligand, can attract pro-
perdin, but not when present as a membrane-anchored protein. Given the fact that there is
considerable heterogeneity in properdin binding on soluble CL-12-opsonized A. fumigatus in the
presence of the Cp40 and NHS, whether the soluble CL-12:properdin crosstalk additionally involves
a complex mixture of different humoral immune components remains question.
Unlike most of the complement components which are predominantly expressed by hepatocytes,
properdin is also produced by different leukocytes (Schwaeble et al., 1994; Schwaeble et al.,
Figure 4 continued
described above. C3b deposition (A, C) or properdin binding (B, D, E) was analyzed and expressed as the GMFI or % positive events with respect to
the C3-Dpl alone by flow cytometry. Results are representative of at least six independent experiments. *p<0.01.
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. Binding of properdin to A.niger in the presence of soluble CL-12 and compstatin analog Cp40.
Figure supplement 2. Soluble CL-12-dependent properdin binding on A.niger.
Figure supplement 3. Effect of soluble CL-12 on properdin binding in C3-absent serum.
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Figure 5. Binding specificity of soluble CL-12 towards properdin variants. (A) Illustrative diagram of monomer-like properdin complex. (B) SEC analysis
of properdin. Inset: SDS-PAGE analysis of properdin under reducing condition. (C) A. fumigatus were incubated with fP-Dpl (10%) restored with purified
serum properdin (10 mg/ml) or properdin variants (fP T: properdin tetramer; fP DT: properdin dimer/trimer; fP M: monomer-like properdin, 10 mg/ml).
C3b deposition were analyzed and expressed as % Positive events with respect to the fP-Dpl alone with mean ± S.E.M from three independent
Figure 5 continued on next page
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1993; Wirthmueller et al., 1997; Stover et al., 2008). However, leukocytes-derived properdin
is ~100 times more active than serum-derived properdin in an AP hemolytic assay (Schwaeble et al.,
1993). Whether the molecular composition and function of leukocyte produced properdin resemble
serum properdin remains unknown. Recently, Harboe et al. observed that properdin reconstituted to
properdin-deficient serum bound HUVECs in an initial C3b-dependent manner, but not detected
with properdin in C3-deficient serum (Harboe et al., 2017). Consistent with this observation, we
found that binding of isolated properdin was remarkably reduced in the presence of properdin-defi-
cient serum on A. fumigatus and further abolished in the presence of the Cp40. Similar results were
also achieved when properdin variants (fP T, fP DT or fP M) were applied. These results suggest that
unknown serum factors may compete or inhibit properdin binding to the AP activator surfaces. It
might be hypothesized that this may protect self-tissue from constitutive complement-mediated
damage, as has been suggested for serum amyloid P component (SAP), which limits properdin func-
tion in the presence of serum (Mitchell and Hourcade, 2008). Given the fact that various leukocytes
express properdin, locally released properdin could bypass regulation by serum factors, thus exert
differential functions at the local tissue level.
Multiple studies have suggested the essential role of properdin oligomerization for complement
activation and amplification, and the tetramer has repeatedly been found to be significantly more
active than both the dimer and the trimer among the physiological forms of properdin
(Pedersen et al., 2017; Pangburn, 1989; Blatt et al., 2016; Ali et al., 2014). We have previously
shown that when properdin was prevented from forming oligomers and only formed the monomeric
form, it was unable to support complement-mediated bacteriolysis and with a strong reduction in
the capability of supporting C3b amplification (Pedersen et al., 2017). These findings further sup-
port the importance of properdin oligomerization for its in vivo function. Given the fact that proper-
din exists as approx. 30% dimers, 50% trimers and 20% tetramers in serum (Harboe et al., 2017;
Pedersen et al., 2017; Pangburn, 1989), our data imply that soluble CL-12 is likely to preferably
recognize properdin organized as higher oligomer which may increase its avidity to interact with sol-
uble CL-12 or/and fluid-phase C3 convertase simultaneously. Our results with the fP T, the fP DT and
the fP M further substantiate this is indeed the case. Properdin is stored in mast cells and neutrophils
(Wirthmueller et al., 1997; Stover et al., 2008), which location are closely associated with blood
vessels and thus rather convenient to play a sentinel role in innate immune defense. Therefore, such
locally released properdin might have differences in oligomerization and posttranslational modifica-
tions compared to its serum form, thus representing a more active form with a higher affinity
towards binding partners.
In conclusion, we provide evidence that it is necessary to revise the notion about properdin show-
ing that it can function in complex with a PRM as shown here with the example of CL-12. We argue
that properdin also may specifically direct AP of complement activation via sensory inputs from CL-




HEK293F (Source: Gibco, Identifier: R79007) was involved in our work. Each lot of Gibco 293 F cells
was tested for cell growth and viability post-recovery from cryopreservation. The Master Seed Bank
has been tested for contamination of bacteria, yeast, mycoplasma and virus and has been character-
ized by isozyme and karyotype analysis.
Figure 5 continued
experiments. (D) sCL-12 (5 mg/ml) was preincubated with the fungus prior to addition of the serum treated with Cp40 (6 mM) plus the properdin variants.
Binding of properdin variants was analyzed in sCL-12-positive region (R1 in FSC vs SSC of the fungus) and expressed as % properdin/CL-12-double
positive events with mean ± S.E.M from three independent experiments. (E) Binding of properdin tetramer (20 mg/ml) was determined on A. niger as
above. Results are representative of at least six independent experiments.
The online version of this article includes the following figure supplement(s) for figure 5:
Figure supplement 1. Binding of properdin variants to A.niger in the presence of soluble CL-12.
Zhang et al. eLife 2020;9:e60908. DOI: https://doi.org/10.7554/eLife.60908 11 of 19
Research article Immunology and Inflammation Microbiology and Infectious Disease
Figure 6. Effect of soluble CL-12 on properdin-directed AP C3 convertase assembly on A.fumigatus. A. fumigatus were incubated with fP-Dpl (10%) in
the presence or absence of sCL-12 (5 mg/ml) as described above. In some experiments, the serum was restored with serum properdin (10 mg/ml) in the
presence of Cp40 (6 mM). Bb deposition was analyzed by flow cytometry. The GMFI was used to assess protein binding and expressed as mean ± S.E.M
from three independent experiments. Results are representative of at least six independent experiments. *p<0.01.
Figure 6 continued on next page
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Production of recombinant properdin
DNA encoding human properdin was synthesized (GenScript) with the endogenous signaling pep-
tide and a C-terminal 6xHis-tag and cloned into the pCEP4 mammalian expression vector using Hin-
dIII and BamHI restriction sites. Oligomeric properdin (fP T or fP DT) was expressed by transient
Figure 6 continued
The online version of this article includes the following figure supplement(s) for figure 6:
Figure supplement 1. Effect of soluble CL-12 on properdin-directed AP C3 convertase assembly on A.niger.
Figure 7. Proposed avenues of alternative pathway activation. Specific initiation: In addition to the non-specific AP activation, the AP is also specifically
triggered by pattern- recognition molecules (PRMs), as soluble CL-12. Upon opsonization of target surfaces, soluble CL-12 specifically recruits
properdin organized as higher oligomer (ex. tetramer) to initiate in situ assembly of C3bBb or promotes surface recruitment of preformed fluid-phase
C3bBb. When the constant turnover of the in situ assembly drives around, C3b production is highly amplified (amplification 1). Non-specific initiation:
AP activation often occurs when C3 thioester is spontaneously activated in the fluid phase and forms initiation C3 convertase C3(H2O)Bb on nearby AP
activator surfaces. The initiation is independent of the trigger, and starts to create AP C3 convertase (C3bBb) based on the low level of non-specifically
anchored nascent C3b in collaboration with factor B (fB) and factor D (fD). When the AP C3 convertase is stabilized through the association of the
complement positive regulator properdin, the productivity of C3b is highly amplified (amplification 2). Both avenues of the specific and non-specific
responses contribute to the feedback C3 amplification loop, which substantially potentiates formation of AP C3 convertase, C5 convertase (C3bBbC3b)
and C5b-9 membrane attack complex (MAC) for complement activation.
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transfection (Pedersen et al., 2019b) and monomeric properdin (monomer-like properdin complex)
was generated by co-transfection of properdin head fragment (TB-TSR3) and tail fragment (TSR4-
TSR6) as described previously (Pedersen et al., 2019a). Oligomeric and monomeric properdin were
expressed in HEK293F cells as described previously (Pedersen et al., 2019b). fP T and fP DT were
purified by gel filtration using a 24 ml Superdex 200 increase column (GE Healthcare) equilibrated in
equilibration buffer (20 mM HEPES/150 mM NaCl, pH 7.5).
Compstatin analog Cp40 and its control peptide
Compstatin analog Cp40 (dTyr-Ile-[Cys-Val-Trp(Me)-Gln-Asp-Trp-Sar-His-Arg-Cys]-mIle-NH2, 1.7
kDa) was produced by our group at the University of Pennsylvania and applied to specifically block
C3 activation (Risitano et al., 2014). Negative control peptide to the Cp40 (Ile-Ala-Val-Val-Gln-Asp-
Trp-Gly-His-His-Arg-Ala-Thr-NH2, 1.5 kDa) was obtained from Tocris Bioscience.
Efficacy of compstatin analog Cp40 on C3b deposition
Normal human serum (NHS) (20%) (from healthy volunteer blood donors with informed consent) was
preincubated with the compstatin analog Cp40 (0–6 mM) or the control peptide (0–6 mM) for 10 min
prior to incubation with Aspergillus fumigatus (A. fumigatus). Complement C3b deposition was then
determined in the presence of TBS/Ca2+ as previously described (Ma et al., 2015), and analysed by
flow cytometry. Data were evaluated using FCS express version 5 (De Novo software).
Preparation of fungal pathogens
Isolates of A. fumigatus strain was obtained from fatal clinical specimens (No. 6871) of invasive pul-
monary aspergillosis (IPA) (Naaraayan et al., 2015) (a kind gift from Professor Luigina Romani,
Microbiology Section, Department of Experimental Medicine and Biochemical Science, University of
Perugia). Isolates of A. niger strain (N32) was obtained from Professor Reinhard Würzner (Innsbruck
Medical University, Innsbruck). Resting conidia were prepared as previously described (Ma et al.,
2015; Zhang et al., 2019). In brief, the Aspergillus strains were grown on sabouraud dextrose agar
supplemented with chloramphenicol by agar-streak for 4 days at 28˚C. Abundant conidia were
obtained under these conditions. The conidia were harvested by washing the slant culture with PBS
supplemented with 0.025% Tween 20 (PBS-T) and gently scraping the conidia from the mycelium
with sterile cotton-tipped applicators. The conidia were then allowed to settle by gravity, followed
by filtration through sterile 40 mM cell strainer to remove hyphal fragments and cell debris. After
extensive washing with PBS-T, the conidia were counted and diluted to the desired concentrations.
The conidia were heat-inactivated at 121˚C for 15 min prior to use. Clinically isolated C. albicans
H29929 was obtained and prepared as described previously (Ma et al., 2011).
Binding of soluble CL-12 to A. fumigatus, A. niger and C. albicans
Binding of soluble CL-12 to A. fumigatus was performed as previously described (Ma et al., 2009;
Ma et al., 2013b). Aspergillus strains were incubated with recombinant soluble CL-12 (5 mg/ml, R
and D system). Bound proteins were detected with CL-12 pAb one and Alexa Fluor 488-conjugated
donkey anti-goat IgG (Invitrogen), and finally analyzed by flow cytometry. Data were evaluated using
FCS express version 5 (De Novo software). In some experiments, the binding was also determined
on A. niger or C. albicans as described previously (Zhang et al., 2019; Ma et al., 2011).
Binding of properdin to A. fumigatus and A. niger
A. fumigatus were incubated with NHS (20%) treated with or without compstatin analog Cp40 (6
mM) or control peptide (6 mM) under TBS/EGTA-Mg2+ (10 mM Tris/150 mM NaCl/10 mM EGTA/5
mM Mg2+, pH7.4) as described above. When incubation with 100% NHS instead, the Cp40 or con-
trol peptide was treated with 20 mM. After washing, properdin binding was detected by sheep anti-
human properdin pAb (R and D system) and Alexa fluor 488-conjugated donkey anti-sheep IgG (Invi-
trogen). Bound proteins were analyzed by flow cytometry as described above. In some experiments,
A. fumigatus were preincubated with soluble CL-12 (5 mg/ml) prior to addition of NHS (20% or
100%), properdin-depleted human serum (fP-Dpl) (10%, CompTech) with or without addition of
serum properdin (10 mg/ml, CompTech) or C3-depleted human serum (C3-Dpl) (0 ~ 100%, Comp-
Tech), and assessed as described above. The binding specificity of soluble CL-12 towards properdin
Zhang et al. eLife 2020;9:e60908. DOI: https://doi.org/10.7554/eLife.60908 14 of 19
Research article Immunology and Inflammation Microbiology and Infectious Disease
oligomers was tested with fP T, fP DT or fP M instead. Alternatively, the binding was also deter-
mined on A. niger as described above.
Serum properdin (CompTech) was thawed once from initial preparation, and preparations that
formed aggregates during storage were excluded from testing through SEC analysis prior to use.
Serum properdin was organized mainly as physiological oligomers (dimers, trimers and tetramers)
under the conditions above (Harboe et al., 2017; Pedersen et al., 2017). Purity and oligomeric sta-
tus of fP T, fP DT and fP M were determined by SDS-PAGE and SEC analysis prior to use as
described above. In some experiments, C3-Dpl (10%) was spiked with exogenous C3 (130 mg/ml,
CompTech) under physiological concentration, and assessed complement activity by measurement
of C3b deposition as described above. The level of properdin was quantified to be ~14.6 mg/ml in
the C3-Dpl (Harboe et al., 2017).
Deposition of Bb on A. fumigatus and A. niger
A. fumigatus was incubated with properdin-restored fP-Dpl in the presence or absence of soluble
CL-12 (5 mg/ml) as described above. Bb deposition was detected by mouse anti-human Bb mAb
(Quidel) and FITC-conjugated goat anti-mouse IgG (Dako) and analyzed by flow cytometry as
described above. Alternatively, the binding was also determined on A. niger as described above.
Statistical analysis
Data were analyzed by GraphPad Prism version 8.0 (GraphPad Software) for statistics. Significant dif-
ferences were analyzed by one-way ANOVA to compare between control and treated samples. P
values < 0.01 were considered statistically significant.
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Schwaeble W, Huemer HP, Möst J, Dierich MP, Ströbel M, Claus C, Reid KB, Ziegler-Heitbrock HW. 1994.
Expression of properdin in human monocytes. European Journal of Biochemistry 219:759–764. DOI: https://
doi.org/10.1111/j.1432-1033.1994.tb18555.x, PMID: 8112326
Selman L, Skjodt K, Nielsen O, Floridon C, Holmskov U, Hansen S. 2008. Expression and tissue localization of
collectin placenta 1 (CL-P1, SRCL) in human tissues. Molecular Immunology 45:3278–3288. DOI: https://doi.
org/10.1016/j.molimm.2008.02.018, PMID: 18423602
Stover CM, Luckett JC, Echtenacher B, Dupont A, Figgitt SE, Brown J, Männel DN, Schwaeble WJ. 2008.
Properdin plays a protective role in polymicrobial septic peritonitis. The Journal of Immunology 180:3313–
3318. DOI: https://doi.org/10.4049/jimmunol.180.5.3313, PMID: 18292556
Zhang et al. eLife 2020;9:e60908. DOI: https://doi.org/10.7554/eLife.60908 18 of 19
Research article Immunology and Inflammation Microbiology and Infectious Disease
Vuagnat BB, Mach J, Le Doussal JM. 2000. Activation of the alternative pathway of human complement by
autologous cells expressing transmembrane recombinant properdin. Molecular Immunology 37:467–478.
DOI: https://doi.org/10.1016/S0161-5890(00)00069-9, PMID: 11090881
Wang Y, Miwa T, Ducka-Kokalari B, Redai IG, Sato S, Gullipalli D, Zangrilli JG, Haczku A, Song WC. 2015.
Properdin contributes to allergic airway inflammation through local C3a generation. The Journal of Immunology
195:1171–1181. DOI: https://doi.org/10.4049/jimmunol.1401819, PMID: 26116506
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